Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q2 2019 · 10-Q
Revenue$135.67K$135.67K−99.4% vs Q2 2018 Net Income-$29.39M-$29.39MN/M vs Q2 2018 EPS Diluted-$0.30-$0.30N/M vs Q2 2018 Operating Income-$28,200,694N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$24,006,061N/M Margins · derivedOperating margin-20785.8%−20764.5 pt vs Q2 2018
Net margin-21660.3%−21633.2 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 8, 2019 · 39 d after period end